Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single-Dose JNJ-73763989 in Healthy Chinese Adults
NCT04586439Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Conjugated siRNA, Peptide-Drug Conjugates, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tomligisiran in Chronic Hepatitis B (CHB) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 4 Weeks, Plasma Concentration of JNJ-73763989 and 1 more. Started Nov 2020; status: completed.
02
Drugs
tomligisiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04586439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586439.